PHL Inno - Lab Notes: Penn plays role in new cancer imaging agent; Carisma names new chairman bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
It’s a big moment for On Target Laboratories, an 11-year-old biotech based in West Lafayette. The FDA approval marks the company’s first novel compound to get across the finish line. The drug is marketed under the brand name Cytalux.
Newswise PHILADELPHIA An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn’s Perelman School of Medicine.
The findings suggest that the Penn-developed tool which uses artificial intelligence and machine learning to decipher the mixture of volatile organic compounds (VOCs) emitting off cells in blood plasma samples could serve as a non-invasive approach to screen for harder-to-detect cancers, such as pancreatic and ovarian.
The results will be presented at the annual American Society of Clinical Oncology meeting on June 4 by
An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy.
An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn's Perelman School of Medicine.